Key features and details | |
Cat. No. | MABL-2623 |
Name | Anti-PCSK9 mAbs |
Clone No. | AFD- 508.20.33b (Fab33) |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | antagonist, functional assay, therapeutic, Block, ELISA |
Species Reactivity | cynomolgus monkeys, Rat, Human, Rhesus Monkey, Mouse |
Basic Information | |
Specificity | This antibody binds human PCSK9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease enzyme encoded by the PCSK9 gene in humans and it plays a role in regulation of circulating cholesterol. It is associated with autosomal dominant hypercholesterolemia, a state of elevated levels of LDL (low-density lipoprotein) cholesterol. Autosomal dominant hypercholesterolemia can result in severe implications such as stroke and coronary heart disease. |
Alternative Name | NARC1; NARC-1; PC9; Proprotein convertase subtilisin/kexin type; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9 |
UniProt | Q8NBP7 |
Immunogen | The original antibody was isolated from a phage display library by panning against biotinylated human PCSK9. |
Application Notes | The binding affinity of this antibody towards PCSK9 protein from human, murine, rhesus, and cynomolgus monkey was done using surface plasmon resonance. This antibody was found to inhibit binding of PCSK9 to LDLR in a competition binding ELISA. This antibody plays a role in effective prevention of LDLR downregulation in HepG2 cells in vitro. When administered in vivo, this antibody prevented LDLR downregulation in mouse liver. This antibody showed a reduction in total serum cholesterol levels in mice when a single dose of 10 mg/kg was administered. It was also found that a combination of this antibody and statin results in a greater reduction in total cholesterol level compared to anti-PCSK9 antibody alone or statin alone treatments (US9266961). |
Antibody First Published | Zhang et al. Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists. Nat Struct Mol Biol. 2017 Oct;24(10):848-856. PMID:28825733 |
Note on publication | Describes the generation of antagonistic antibodies that encroach on the EGF(A)- binding site and inhibit LDLR binding. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
